Puma Biotechnology Q1 2026 Earnings Call Summary
In the first quarter of 2026, Puma Biotechnology reported total revenue of $44.8 million, with net product sales from NERLYNX at $42 million and royalty income at $2.8 million. The company experienced a sequential decline in both product and royalty revenues due to inventory drawdowns.
Tickers: $PBYI